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Localization of platelet antigens in human kidney disease
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Localization of platelet antigens in human kidney disease. The
localization of a platelet antigen or antigens in kidneys from 106
patients with renal disease was evaluated with immuno-
fluorescent microscopy by using a rabbit antibody to human
platelets. The antiplatelet lgG fixed to the surface membrane of
platelets but did not react with erythrocytes, leukocytes, plasma,
normal kidney, or a variety of normal tissue targets. Significant
glomerular and vascular deposition of platelet antigen (or anti-
gens) was observed along the endothelium or as vascular plugs in
kidney tissue from patients with hemolytic uremic syndrome,
membranoproliferative glomerulonephritis (types I and II), dia-
betic nephropathy, hypertensive renal disease, scleroderma, and
other diseases. Dual-label immunofluorescent studies revealed
that platelet antigen (or antigens) and fibrinogen/fibrin-related an-
tigen (FRA) were usually, though not always, present in similar
loci. Platelet antigens were not observed at sites of intense FRA
deposition: in the mesangium in anaphylactoid purpura and in
glomerular crescents in Goodpasture's syndrome. Platelet anti-
gen was detected in the peritubular capillaries of most patients
with diabetic nephropathy.
Localisation des antigènes plaquettaire au cours des maladies
rénales chez l'homme. La localisation de l'antigene plaquettaire
dans les reins de 106 malades atteints de néphropathies a été
évaluée par microscopie en immunofluorescence au moyen d'un
anticorps de lapin anti plaquettes humaines. L'IgG anti-
plaquettes se fixe a Ia membrane plaquettaire mais ne réagit pas
avec les ërythrocytes, les leucocytes, le plasma, le rein normal
ou divers tissus cibles normaux. Des dépôts glomérulaires et
vasculaires d'antigenes plaquettaires ont été observes Ic long de
l'endothélium ou sous la forme d'obstructions vasculaires dans
le tissu renal prélevé chez des malades atteints de syndrome he-
molytique et uremique, de glomerulonephnte membrano-pro-
liférative (types I et II), de nephropathie diabetique, de maladie
rénale hypertensive, de scldrodermie et d'autres affections. Les
etudes en immuno-fluorescence double révèlent que l'antigéne
plaquettaire et l'antigene lie au système fibnnogene/fibrine(FRA) sont habituellement mais non toujours observes dans des
sites de dépôts intenses de FRA: dans le mésangium au cours de
purpura anaphylactoIde et dans les croissants glomerulaires du
syndrome de Goodpasture. L'antigène plaquettaire a dtd détecté
dans les capillaires péritubulaires de la plupart des malades at-
teints de néphropathie diabétique.
The role of the platelet in the pathogenesis of hu-
man renal disease is unclear. In disorders associat-
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ed with microangiopathy, such as hemolytic uremic
syndrome, hyperacute homograft rejection, post-
partum renal failure and malignant hypertension, fi-
brinogen/fibrin-related antigen (FRA) and factor
VIII are found within similar loci in vessels and
glomeruli, suggesting that intravascular coagulation
plays an important role [1]. In contrast, in certain
diseases the presence of FRA in glomerular cres-
cents or within the mesangium without factor VIII
may reflect either coagulation-independent path-
ways or activation of the clotting system by alterna-
tive mechanisms.
George et al [2] demonstrated that the decreased
platelet survival in renal disease could be correlated
with vascular and endothelial injury and, in some
patients, returned to normal following nephrecto-
my. In the present study, the localization of platelet
antigen (or antigens) in the kidney in a variety of
diseases is demonstrated for the first time by immu-
nohistochemical techniques.
Methods
Platelet isolation. Platelets were separated from
other cells by a modification of the method of Zim-
merman and Kolb [3]. Pooled human 0, Rh-nega-
tive platelet concentrate (200 ml) obtained from the
blood bank at the University of Minnesota Hospi-
tals, was centrifuged at x620g for 10 mm. The
platelet-rich supernate, containing less than 0.1%
erythrocyte and lymphocytes, was centrifuged at
x2000g for 10 mm, washed three times in 30 ml of a
0. 145-M sodium chloride solution containing 0.02 M
sodium phosphate (pH, 7.40; PBS), and was recov-
ered by centrifugation at x 2000g. The platelet pellet
was then suspended in 5.0 ml of PBS and separated
into 0.5-mI aliquots in siliconized tubes, quick-fro-
zen in a dry ice-acetone mixture, and stored at
_7Ø0 C until used.
Preparation of platelet antiserum (antiplatelet).
New Zealand white rabbits were injected s.c. in
four sites with a total of 0.5 ml of platelet suspen-
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Fig. 1. A Peripheral blood smear stained with antiplatelet (FITC), demonstrating intense fluorescence of a clump of platelets. Note that
the region surrounding the platelets, which contains erythrocytes and leukocytes as visualized by phase microscopy, failed to react with
the antiplatelet (x 900). B Electron micrograph of platelets incubated with anti-platelet IgG and then with horseradish peroxidase labeled
goat anti-rabbit IgG. The dense reaction product is located along the surface of platelets with a small amount in the intratubular
membrane system (x36,000).
sion mixed with an equal volume of complete strates (volume of antiplatelet/volume of substrate):
Freund's adjuvant. Injections were given at inter- (1) 0, Rh-negative erythrocytes (v/v, 10/1) sequen-
vals of 2 weeks over a period of 14 weeks. The tially for 30 mm at 40, 22°, and 37° C; (2) myelog-
pooled antiplatelet was decomplemented by in- enous leukemia cells obtained by leukophoresis
cubation at 56° C for 30 mm and sequentially ab- from a patient with acute myelogenous leukemia (vI
sorbed three times with each of the following sub- v,10/1) for 30 mm at room temperature and over-
Table!. Immunofluorescent identification of platelet antigens and fibrinogenlfibrin-related antigens (FRA) in the kidney
Disease
Total number
of patients
Number of patients demonstrati
positive immunofluorescence
ng
Platelet
—--
Glomerular Vasculara Glomerular
FRA
Vasculara
Hemolytic uremic syndrome 8 8 8 7 2
Diabetic nephropathy 18 7 14 3 8
Membranoproliferative glomerulonephritis
Typel 6 3 5 4 1
TypelI 4 4 4 1 0
Polycystic disease with hypertension 2 0 2 1 0
Chronic renal failure with hypertension 3 1 3 0 0
Scleroderma 1 1 1 1 1
Malignant hypertension with microangiopathy 1 1 1 1 1
Familial nephritis 4 1 3 0 0
Interstitial diseaseb 8 1 3 0 0
Lupus erythematosus 9 1 5 5 2
Goodpasture's syndromer 4 1 1 2 0
Poststreptococcal glomerulonephritis 1 0 0 1 0
Vasculitis 3 1 1 1 0
Nephrotic syndrome of varied etiologyd 18 1 1 3 0
IgA nephropathy 5 0 3 0 0
Anaphylactoid purpurac 11 1 2 9 1
a Small vessels and peritubular capillaries
b Includes patients with interstitial nephritis, renal dysplasia, and medullary cystic disease
In Goodpasture's syndrome, FRA was present in crescents in 2 patients; and platelet antigens within the glomerular capillary lumen,
in 1. In anaphylactoid purpura, FRA was present in the mesangium in 9 patients and in crescents in 2; and platelet antigen(s) within the
glomerular capillary lumen of 1.
Includes patients with idiopathic nephrotic syndrome (5); membranous nephritis (5); focal sclerosis (8); one patient with focal scle-
rosis had vascular and glomerular immunofluorescence for platelet antigen.
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Fig. 2. Kidney sections stained sequentially by the dual-label technique forfibrinogenifibrin-related antigen (FRA) (FITC) and platelet
antigen(s) (TMR). Hemolytic uremic syndrome: A FRA deposition within the glomerular capillary, along the endothelium (arrows), and
in the mesangium (M) (x900). B Platelet antigen is present within three glomerular capillaries in the same glomerulus (X900). Malignant
hypertension: C FRA deposition within the wall of two small renal arteries (x 1000). D Platelet deposits are present within similar sites
of the same vessels (x 1000).
night at 4° C; (3) tissue culture lymphoblasts at
37° C for 30 mm and overnight at 4° C (culture line
1788 from the tissue culture laboratory, Mr. R. Con-
die, director, University of Minnesota; 108 cells!
ml); (4) AB plasma absorbed in fluid phase (vlv, 10!
1) or conjugated to sepharose 4B by cyanogen bro-
mide.
Characteristics of antiplatelet: (1) Immuno-
histochemical studies. Antiplatelet was shown to
react with the surface of platelets by the indirect
immunofluorescent technique [4] by using anti-
platelet in dilutions up to 1:1024 followed by fluo-
rescein-isothiocyanate-labeled (FITC) goat anti-
rabbit IgG (GARIgG) on peripheral blood smears
and bone marrow sections fixed in acetone for 10
mm (Fig. 1). This immunofluorescence was com-
pletely inhibited by the prior absorption of the anti-
serum with whole platelets (0, Rh negative). No re-
activity was observed with monocytes, lympho-
cytes, polymorphonuclear leukocytes, or erythro-
cytes.
Additional control studies demonstrated: no
crossreactivity with a panel of lymphoid cells defin-
ing 22 HLA antigens (Histocompatibility Laborato-
ry, University of Minnesota); absence of erythro-
cytes and leukocyte agglutinins (Blood Bank, Anti-
body Laboratory, University of Minnesota); no
immunoprecipitation in double diffusion studies in
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Fig. 2. Membranoprol(ferative glomerulonephritis (Type I): E FRA is present along the endothelium of the glomerular capillaries (x800).
F Note the similarity in platelet antigen deposition in the same glomerulus (arrows); in other regions the deposition of FRA and platelets
is discordant (X800).
gel against normal human plasma; absence of immu-
nofluorescent staining of normal tissue targets in-
cluding kidney, liver, skin, muscle, brain, and pla-
centa; and presence of platelet aggregates within
vessels of the normal placenta.
(2) Immunoelectron microscopy. Human plate-
lets from platelet concentrate were fixed in para-
formaldehyde-lysine-periodate fixative (PLP) for 2
hours at 40 C and washed extensively in 0.025 M
phosphate buffer with 6% sucrose [5]. The platelet
pellet was then incubated with either the IgG frac-
tion of the antiplatelet serum or normal rabbit
serum in a dilution of 1:32 for 1 hour at 4° C, rinsed,
and incubated in horseradish peroxidase-labeled
goat antirabbit IgG for 1 hour at 4° C [6] (obtained
from Dr. Robert L. Vernier and Ms. Sue Sisson,
University of Minnesota). Following rinsing in
phosphate-sucrose buffer, the treated platelets were
reacted with 0.03% diaminobenzidine tetrahy-
drochloride (DAB: Sigma Chemical Co., St. Louis,
Missouri) in a 0.05-M Tris (2-amino-2-(hydroxy-
methyl)-1-3 propanediol) (Eastman Kodak, Roches-
ter, NY) buffer (pH, 7.6) at 4° overnight and then
reacted with fresh DAB containing 0.01% hydrogen
peroxide for 2 hours and refixed in 1.33% osmium
tetroxide in S-collidine buffer (pH, 7.4) for 1 hour at
4° C. The platelets were stained for 1 hour with
0.5% aqueous uranyl acetate, rinsed, dehydrated,
and embedded in Epon 812 [6]. All specimens were
thin-sectioned on an LKB ultratome and observed
without further staining in a Phillips 301 electron
microscope.
The reaction product was localized to the surface
of all platelets incubated with antiplatelet, regard-
less of the time of PLP fixation (before or after fixa-
tion); no localization to the surface of the few white
cells studied was noted, and no reaction product
was found on the surface of platelets incubated with
either normal rabbit serum or with the DAB sub-
strate control (Fig. 1).
Immunofluorescent studies on kidney. Kidney
tissue obtained by percutaneous needle biopsy or
nephrectomy was available for study from 106 pa-
tients with different diseases: hemolytic uremic syn-
drome (HUS), 8 patients; diabetic nephropathy, 18;
membranoproliferative glomerulonephritis, type I
(MPGN-I), 6, and type II (MPGN-II), 4: familial
nephritis, 4; systemic lupus erythematosus (diffuse
proliferative glomerulonephritis, 4, focal prolifera-
tive glomerulonephritis, 4, and membranoprolifera-
tive glomerulonephritis, 1); idiopathic nephrotic
syndrome with minimal change, 5; nephrotic syn-
drome with focal sclerosis, 8: membranous ne-
phropathy, 5; IgA nephropathy, 5; anaphylactoid
purpura, 11; Goodpasture's syndrome, 4: vascu-
litis, 3; renal dysplasia, 2; medullary cystic disease,
2; interstitial nephritis, 4; scieroderma, 1; post-
streptococcal glomerulonephritis, 1: hypertension
associated with polycystic disease, 2; chronic renal
failure of unknown etiology, 3, and micro-
angiopathy, 1.
Tissue samples were frozen in isopentane pre-
cooled in liquid nitrogen and sectioned at 4 in a
Lipshaw cryostat. Immunofluorescent studies were
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Fig. 3. Kidney sections stained sequentially by the dual-label techniques .for FRA (FITC) and platelet antigen(s) (TMR): Henoch-
Schonlein purpura: A Intense FRA deposition is present within the mesangium (x800). B In the same glomerulus, no platelet antigen(s)
is observed (x800). Goodpasture's syndrome with crescentric nephritis: C Intense FRA deposition is within a glomerular crescent (out-
lined by arrows); the glomerulus (G) is negative (x 1300). D The same glomerulus showing absence of platelet antigen(s) within the
crescent (arrows); minimal reactivity is seen within the glomerulus (x 1300).
performed by methods previously described [4, 7].
Frozen sections were fixed in acetone for 10 mm
and stained with FITC-conjugated antisera to IgG,
1gM, C3, and fibrinogenlfibrin-related antigen
(FRA). Dual-label studies were carried out on renal
histologic sections with FITC-labeled goat anti-
human FRA followed by antiplatelet and tetrame-
thyl rhodamine-conjugated (TMR) GARIgG [8].
All tissue sections were coded and examined by
phase and immunofluorescent microscopy without
knowledge of diagnosis or source by two investiga-
tors using a Zeiss reflected fluorescence microscope
with appropriate FITC and TMR interference and
absorption filters as previously described [8]. A
minimum of three glomeruli per section (range, 3 to
32) were examined with one exception; the tissue of
a patient with MPGN-I contained one glomerulus.
The code was broken after the data were tabulated.
The intensity of glomerular and vascular staining
were scored as follows: negative, not significantly
different from the background; trace, barely above
background; I to 3 plus, increasing degrees of posi-
tivity.
Results
Platelet antigen (or antigens) was present within
glomeruli, along endothelial surfaces of the gb-
merular capillary or as plugs within the capillary lu-
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Fig. 3. Diabetes mellittis: E Platelet antigen(s) is present in the pentubular capillaries (< 1000). F FRA is not observed in peritubular
capillaries of the same kidney section depicted in E (x 1000).
men in patients with HUS, MPGN-I and MPGN-II,
diabetic nephropathy, and less frequently other dis-
eases (Table 1). In addition, platelet antigen was ob-
served along the intima and within the lumen of ar-
terioles and peritubular capillaries in these patients,
as well as in patients with other diseases, especially
familial nephritis, hypertension associated with
polycystic disease, chronic renal insufficiency or
microangiopathy, and lupus erythematosus. By se-
quentially staining the same section with anti-FRA
(FITC) followed by antiplatelet and GARIgG(TMR), both antigens could be demonstrated in
similar sites in HUS, MPGN, malignant hyper-
tension with microangiopathy, and in scleroderma
(Fig. 2, A-F). In HUS, 1gM was present in the same
loci as platelet antigens and FRA. In MPGN-I and
MPGN-II, however, platelet antigen often was not
in the same locus as FRA (Fig. 2, E and F). In addi-
tion, platelet antigen was not observed in sites of
intense FRA deposition: within the mesangium of 9
patients with anaphylactoid purpura; and in cres-
cents of 2 patients with Goodpasture's syndrome
and 2 patients with anaphylactoid purpura (Fig. 3,
A—D). In diabetic nephropathy, platelet antigen was
commonly observed within the lumen of arterioles
or as peritubular capillary plugs with or without de-
tectable FRA (Fig. 3, E and F).
Evaluation of light microscopic sections from
those patients with significant platelet antigen depo-
sition by immunofluorescence failed to reveal any
consistent association with polymorphonuclear leu-
kocyte infiltration or with areas of cortical necrosis.
In the one disorder in which polymorphonuclear
leukocyte infiltration was present (poststreptococ-
cal glomerulonephritis), platelet antigen was not
detected. Within the interstitium, round cell infil-
tration was observed in patients with familial ne-
phritis (4/4), diabetes mellitus (10/18), membranopro-
liferative glomerulonephritis (3/10), and systemic
lupus erythematosus (1/9). These infiltrates were,
however, usually focal in nature and did not cor-
relate with positive immunofluorescence.
Discussion
By immunohistochemical techniques, the platelet
antiserum used in these studies reacted with surface
component (or components) of the platelet and not
demonstrably with other cells or tissues. The nature
of the antigenic determinants is unknown, however.
Platelet antigen (or antigens) was demonstrated
within glomeruli and vessels in a number of dis-
eases, especially HUS, MPGN, diabetes mellitus,
and in diseases associated with severe hyper-
tension. In HUS, FRA and platelet antigens were
usually seen in the same site, whereas in other dis-
eases such as MPGN, the deposition was often dis-
cordant. Marked FRA deposition, however, was
noted in the absence of platelet antigens: within gb-
merular crescents in Goodpasture's syndrome and
in the mesangium of patients with anaphylactoid
purpura. These findings are similar to prior observa-
tions in which the deposition of FRA and factor
VIII antigen was shown to be concordant in certain
diseases associated with microangiopathy (HUS,
hyperacute rejection, scleroderma) and discordant
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in other diseases (crescentic nephntis, anaphylac-
toid purpura).
The variance between FRA and platelet antigen
deposition may be explained by alternative mecha-
nisms that bypass the classical coagulation cascade
and the plasminogen-plasmin system [9, 10]. This is
reflected by studies of nephrotoxic serum nephritis in
which crescent formation is not inhibited by heparin
but is inhibited by Arvin, a Malayian pit viper
venom extract that cleaves fibrinopeptide A from
fibrinogen [11, 12]. In addition, the antiplatelet used
in the present study reacts with an antigenic com-
ponent (or components) of the platelet membrane,
which could bind to regions of damaged endothelium
without necessarily activating the coagulation cas-
cade.
There is increasing evidence that certain platelet
constituents play an important role in vascular dis-
orders [13], but the precise relationship to the path-
ogenesis of renal disease is not settled. Although
extensively studied, the administration of anti-
coagulants to animals with immune complex dis-
ease or anti-GBM nephritis has led to conflicting
and often divergent results, which are difficult to in-
terpret because of the variables involved (reviewed
in Ref. 14). Conclusive and uniform evidence for a
beneficial effect of anticoagulation is lacking [15-
19]. In fact, a major role for the platelet in the path-
ogenesis of these experimental diseases has been
questioned, except in sites of endothelial detach-
ment [20—22]. In human renal disease, evidence (re-
viewed in Refs. 14 and 23) for participation of plate-
lets is derived from studies demonstrating short-
ened survival in vivo [2, 23], increased aggregation
or altered function [24—28], and localization in dis-
eased kidney by morphologic, especially ultrastruc-
tural, techniques (reviewed in Refs. 23, 30—33). Al-
though the platelet plays a role in the pathogenesis
and progression of certain diseases characterized
by microangiopathy, such as HUS and thrombotic
thrombocytopenic purpura, its involvement in other
renal diseases is less clear.
George et al [2] demonstrated decreased platelet
survival in a number of diseases, including HUS,
MPGN, glomeruloscierosis, diffuse proliferative
glomerulonephritis, acute transplant rejection, and
in some cases of diabetes mellitus. Although the de-
creased survival appeared to correlate with vascu-
lar-endothelial injury, no improvement in renal
function was observed in patients with membrano-
proliferative glomerulonephritis treated with anti-
platelet agents in spite of a slight but significant im-
provement in platelet survival. A preliminary study
by Donadio et al [34], however, demonstrated slight
improvement or stabilization of renal function in pa-
tients with MPGN treated with platelet inhibitor
drugs and anticoagulants.
Increased platelet aggregation by ADP and colla-
gen has been observed in a variety of renal diseases,
although correction of the platelet abnormality with
aspirin was not associated with clinical improve-
ment [26, 27]. Evidence for platelet activation has
also been deduced on the basis of a reduction in
platelet serotonin in membranoproliferative glomer-
ulonephritis and other diseases, in spite of normal
or elevated levels in the plasma [29]. Recently,
diminished vascular prostacyclin has been observed
in juvenile onset and streptocytocin-induced diabe-
tes mellitus [35, 36]. These findings in concert with
increased platelet aggregation [28] and increased
synthesis of prostaglandin E by diabetic platelets
[37] may set the stage for enhanced deposition of
platelets in small vessels and capillaries of the kid-
ney, as suggested by our immunofluorescent stud-
ies. Whether altered platelet-vascular prostaglandin
balance plays a role in the initiation or perpetuation
of the microangiopathy of juvenile onset diabetes
mellitus remains to be proven.
It has been difficult to demonstrate consistently
either intact platelets or fragments thereof in dis-
eased kidneys by morphologic techniques [23]. Duf-
fy et al [30] observed intraglomerular fibrin-platelet
aggregates in subendothelial areas in 12 of 25 pa-
tients with nephrotic syndrome, findings that we
were able to confirm in only one of our patients with
nephrotic syndrome by immunofluorescent meth-
ods. In HUS, however, platelets have been recog-
nized in vessels of the kidney by several investiga-
tors [23, 31—33]. The limited observations by mor-
phologic techniques in other diseases probably are a
consequence of disruption of platelets after contact
with the vessel wall. In the present study, an immu-
nohistochemical method was used for the detection
of platelet antigens. The sensitivity of this approach
probably is related to the ability to detect platelet
antigens in intact as well as disrupted platelets that
may not be recognizable by other morphologic tech-
niques.
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